Publication: A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results
Issued Date
2007-01-01
Resource Type
ISSN
10956859
00908258
00908258
Other identifier(s)
2-s2.0-33846181020
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gynecologic Oncology. Vol.104, No.1 (2007), 15-23
Suggested Citation
Vutisiri Veerasarn, Vicharn Lorvidhaya, Pimkhuan Kamnerdsupaphon, Nan Suntornpong, Supatra Sangruchi, Prasert Lertsanguansinchai, Chonlakiet Khorprasert, Lak Sookpreedee, Suthipol Udompunturak A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results. Gynecologic Oncology. Vol.104, No.1 (2007), 15-23. doi:10.1016/j.ygyno.2006.06.045 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25071
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results
Abstract
Objective: Concurrent chemoradiation is the standard treatment for locally advanced cervical cancer. This study was a preliminary result of a randomized two arms, prospective, open-label phase III trial comparing the activity and safety of the concurrent chemoradiation of Tegafur-Uracil and carboplatin or carboplatin alone in locally advanced cervical cancer. Materials and methods: The stage IIB-IIIB cervical cancer patients were randomized to have Tegafur-Uracil 225 mg/m2/day orally, 5 days a week and carboplatin 100 mg/m2IV over 30-60 min, weekly on day 1 concurrent with standard radiotherapy (Group A) or carboplatin alone concurrent with standard radiotherapy (Group B). Results: Four hundred and sixty-nine patients were randomized to Group A (n = 234) or Group B (n = 235). The tumor response at 3-month follow-up time showed no significant difference. The only prognostic factor to improve the complete response rate was the hemoglobin level. The patients in Group A, who had Hb < 10 gm/dL had the relatively better change to complete response of 1.48 compared to that in Group B (P 0.025, 95% CI 1.07, 2.04). No severe toxicity or adverse event had been reported. The median follow-up time for Group A and Group B was 12.6 and 11.8 months, respectively. There was no statistical difference in PFS and OS. Conclusion: Concurrent chemoradiation by Tegafur-Uracil and carboplatin showed no difference in tumor response rate or treatment toxicity compared to carboplatin alone. The combination drugs might have benefit in poor prognostic patients such as the baseline Hb < 10 gm/dL. © 2006 Elsevier Inc. All rights reserved.